Philip Bruggmann
Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study.
Winter B, Hovaguimian F, Kouyos R, Schmidt A, Bernasconi E, Braun D, Calmy A, Notter J, Stoeckle M, Surial B, Christinet V, Cavassini M, Depmeier C, Läuchli S, Boffi El Amari E, Reinacher M, Rasi M, Bruggmann P, Haerry D, Bize R, Low N, Lehner A, Quednow B, Fehr J, Hampel B. Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study. Swiss Med Wkly 2022; 152:w30192.
27.06.2022Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study.
27.06.2022Swiss Med Wkly 2022; 152:w30192
Winter Babette L, Hovaguimian Frédérique, Kouyos Roger D, Schmidt Axel Jeremias, Bernasconi Enos, Braun Dominique L, Calmy Alexandra, Notter Julia, Stoeckle Marcel, Surial Bernard, Christinet Vanessa, Cavassini Matthias, Depmeier Carsten, Läuchli Severin, Boffi El Amari Emmanuelle, Reinacher Matthias, Rasi Manuela, Bruggmann Philip, Haerry David, Bize Raphaël, Low Nicola, Lehner Andreas, Quednow Boris B, Fehr Jan S, Hampel Benjamin
HCV disease burden and population segments in Switzerland
Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batänjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. Liver Int 2021
27.11.2021HCV disease burden and population segments in Switzerland
27.11.2021Liver Int 2021
Bihl Florian, Semmo Nasser, Semela David, Scheidegger Claude, Razavi Homie, Negro Francesco, Mullhaupt Beat, Lavanchy Daniel, Dufour Jean-François, Castro Batänjer Erika, Bruggmann Philip, Blach Sarah
Perioperatives Schmerz-Management unter Buprenorphin-Langzeit-Therapie
Berendes A, Oeltjenbruns J, Beck T, Bruggmann P. Perioperatives Schmerz-Management unter Buprenorphin-Langzeit-Therapie. Suchtmedizin 2021; 23:225-232.
01.11.2021Perioperatives Schmerz-Management unter Buprenorphin-Langzeit-Therapie
01.11.2021Suchtmedizin 2021; 23:225-232
Berendes Andrea, Oeltjenbruns Jochen, Beck Thilo, Bruggmann Philip
Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C
Bobzin C, Semmo N, Semela D, Scheidegger C, Rauch A, Negro F, Moradpour D, Mäschli B, Lavanchy D, Künzler-Heule P, Keiser O, Fraga Christinet M, Cerny A, Bruggmann P, Bösiger C, Thurnheer M. Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. Swiss Medical Forum 2021; 21:184-186.
17.03.2021Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C
17.03.2021Swiss Medical Forum 2021; 21:184-186
Bobzin Carina, Semmo Nasser, Semela David, Scheidegger Claude, Rauch Andri, Negro Francesco, Moradpour Darius, Mäschli Bettina, Lavanchy D, Künzler-Heule Patrizia, Keiser Olivia, Fraga Christinet Montserrat, Cerny Andreas, Bruggmann Philip, Bösiger Christophe, Thurnheer Maria Christine
Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort
Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer M, Vernazza P, Scheidegger C. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort. Swiss Med Wkly 2021; 151:w20460.
04.03.2021Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort
04.03.2021Swiss Med Wkly 2021; 151:w20460
Bregenzer Andrea, Bruggmann Philip, Castro Erika, Moriggia Alberto, Rothen Madeleine, Thurnheer Maria Christine, Vernazza Pietro, Scheidegger Claude
Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions
Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Mullhaupt B, Negro F, Semela D. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. Swiss Med Wkly 2019; 149:w14694.
23.01.2019Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions
23.01.2019Swiss Med Wkly 2019; 149:w14694
Rusch Urs, Robbins Sarah, Razavi Homie, Vernazza Pietro, Blach Sarah, Bruggmann Philip, Mullhaupt Beat, Negro Francesco, Semela David
Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PloS one 2018; 13:e0209374.
31.12.2018Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
31.12.2018PloS one 2018; 13:e0209374
Mullhaupt Beat, Bruggmann Philip, Bihl Florian, Blach Sarah, Lavanchy Daniel, Razavi Homie, Robbins Scott Sarah, Semela David, Negro Francesco
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy 2018; 62:94-103.
29.10.2018Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
29.10.2018Int J Drug Policy 2018; 62:94-103
Grebely Jason, Feld Jordan J, Bruneau Julie, Daulouede Jean-Pierre, Powis Jeff, Bruggmann Philip, Matthews Gail V, Kronborg Ian, Shaw David, Dunlop Adrian, Hellard Margaret, Applegate Tanya L, Crawford Sione, Dore Gregory J, Lacombe Karine, Dalgard Olav, Conway Brian, Cunningham Evan B, Fraser Chris, Moriggia Alberto, Gane Ed, Stedman Catherine, Cooper Curtis, Castro Erika, Schmid Patrick, Petoumenos Kathy, Hajarizadeh Behzad, Marks Phillipa, Erratt Amanda, D3FEAT Study Group
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
Marzel A, Kouyos R, Günthard H, Perreau M, Klimkait T, Yerly S, Böni J, Hoffmann M, Cavassini M, Calmy A, Bernasconi E, Roth J, Rauch A, Bruggmann P, Weber R, Kusejko K, Swiss HIV Cohort Study. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infect Dis 2018; 5:ofy078.
19.05.2018The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
19.05.2018Open Forum Infect Dis 2018; 5:ofy078
Marzel Alex, Kouyos Roger D, Günthard Huldrych F, Perreau Matthieu, Klimkait Thomas, Yerly Sabine, Böni Jürg, Hoffmann Matthias, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Roth Jan A, Rauch Andri, Bruggmann Philip, Weber Rainer, Kusejko Katharina, Swiss HIV Cohort Study
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly 2017; 147:w14543.
09.11.2017Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
09.11.2017Swiss Med Wkly 2017; 147:w14543
Bruggmann Philip, Stoeckle Marcel, Semela David, Schmid Patrick, Razavi Homie, Rauch Andri, Mullhaupt Beat, Lavanchy Daniel, Kouyos Roger, Fehr Jan, Deltenre Pierre, Blach Sarah, Negro Franco
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Mullhaupt B, Razavi H, Semela D. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly 2015; 145:w14221.
04.12.2015Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
04.12.2015Swiss Med Wkly 2015; 145:w14221
Bruggmann Philip, Negro Francesco, Bihl Florian, Blach Sarah, Lavanchy Daniel, Mullhaupt Beat, Razavi Homie, Semela David
Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PloS one 2015; 10:e0125214.
24.06.2015Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
24.06.2015PloS one 2015; 10:e0125214
Mullhaupt Beat, Bruggmann Philip, Bihl Florian, Blach Sarah, Lavanchy Daniel, Razavi Homie, Semela David, Negro Francesco
"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis
Rasi M, Künzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J, Saxer S, Nicca D. "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. BMC Infect Dis 2014; 14:507.
18.09.2014"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis
18.09.2014BMC Infect Dis 2014; 14:507
Rasi Manuela, Künzler-Heule Patrizia, Schmid Patrick, Semela David, Bruggmann Philip, Fehr Jan, Saxer Susi, Nicca Dunja